Clinical stage therapeutics company sets terms for $53 million IPO

Lyra Therapeutics Inc. set terms for its planned initial public offering on Monday, saying it will offer 3.5 million shares priced at…

$14 to $16 each.

The clinical stage therapeutics company, which specializes in ear, nose and throat diseases, has applied to list on Nasdaq under the ticker symbol “LYRA.”

BofA, Jefferies, William Blair and BTIG are underwriters on the deal.

Proceeds will be used to fund clinical trials, for R&D and for…

Continue reading at MARKETWATCH.COM

 

 

You May Also Like

About the Author: Admin